ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company pr ...

Core Insights - Nutriband Inc. has made significant progress in the commercialization of its AVERSA technology, aimed at improving the safety of transdermal drugs prone to abuse, particularly pain medications [4][6][10] Company Achievements - The company has established a partnership with Kindeva Drug Delivery to develop AVERSA Fentanyl, which is expected to be the first opioid pain patch with abuse deterrent properties [5][8] - Nutriband has expanded its intellectual property portfolio, securing patents in 46 countries, including recent approvals in China, Hong Kong, and the United States [9][15] - The company raised $8.4 million in April 2024 through a non-brokered private placement, primarily from existing shareholders, to support its development efforts [8] Financial Outlook - AVERSA Fentanyl is projected to achieve peak annual sales between $80 million and $200 million, while AVERSA Buprenorphine is estimated to reach peak sales of $70 million to $130 million [6] - The Pocono Pharma subsidiary is expected to have a strong revenue year in 2025 due to expanding collaborations in contract manufacturing services [11] Future Goals - Nutriband aims to initiate a pivotal Human Abuse Liability clinical trial for AVERSA Fentanyl in 2025, supporting an NDA filing with the FDA [10] - The company plans to explore international partnerships for its AVERSA intellectual property as it approaches the NDA filing [10]